Nathan D Seligson
Overview
Explore the profile of Nathan D Seligson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paragji A, Shastri V, Nasri E, Ligon J, Elliott L, Castillo-Caro P, et al.
Mol Oncol
. 2025 Mar;
PMID: 40080912
Ewing sarcoma (EwS) is a rare and aggressive malignancy, which frequently affects children. One of the few recurrent genomic variants in EwS is genomic copy number deletion of CDKN2A; however,...
2.
Nelson R, Seligson N, Bottiglieri S, Carballido E, Cueto A, Imanirad I, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518158
In the original publication [...].
3.
Seligson N, Chen J, Goodrich A, Van Tine B, Campbell J, Richards A, et al.
J Immunother Cancer
. 2024 Sep;
12(9).
PMID: 39343511
Background: In this open-label, randomized, non-comparative, multicenter phase II study (Alliance A091401) we report on three expansion cohorts treated with nivolumab (N) with and without ipilimumab (N+I) and provide a...
4.
Seligson N, Asmann Y, Almerey T, Zayas Y, Edgar M, Attia S, et al.
Surg Oncol
. 2024 Aug;
56:102125.
PMID: 39213836
Introduction: For retroperitoneal sarcomas (RPS), aggressive surgical resection offers the only chance for a cure; however, 5-year survival remains below 65%. Therefore, there is a critical need to identify drivers...
5.
Seligson N, Zhang X, Zemanek M, Johnson J, VanGundy Z, Wang D, et al.
Front Pharmacol
. 2024 Jan;
14:1334440.
PMID: 38259277
Polymorphisms in genes responsible for the metabolism and transport of tacrolimus have been demonstrated to influence clinical outcomes for patients following allogeneic hematologic stem cell transplant (allo-HSCT). However, the clinical...
6.
Walker V, Jin D, Millis S, Nasri E, Corao-Uribe D, Tan A, et al.
Transl Oncol
. 2023 Oct;
38:101795.
PMID: 37797367
EWSR1 fusions are highly promiscuous and are associated with unique malignancies, clinical phenotypes, and molecular subtypes. However, rare fusion partners (RFP) of EWSR1 has not been well described. Here, we...
7.
Seligson N, Kolesar J, Alam B, Baker L, Lamba J, Fridley B, et al.
Pharmacogenomics
. 2023 Sep;
24(13):731-738.
PMID: 37702060
Precision medicine has revolutionized clinical care for patients with cancer through the development of targeted therapy, identification of inherited cancer predisposition syndromes and the use of pharmacogenetics to optimize pharmacotherapy...
8.
Bergsma E, Elgawly M, Mancuso D, Orr R, Vuskovich T, Seligson N
Ann Pharmacother
. 2023 Jul;
58(4):407-415.
PMID: 37466080
Objective: The objective was to review the pharmacology, efficacy, and safety of atezolizumab (Tecentriq) for the treatment of adult and pediatric patients aged 2 years and older with unresectable or...
9.
Cook K, Grusauskas V, Gloe L, Duong B, Gresh R, Kolb E, et al.
Clin Transl Sci
. 2023 Jul;
16(8):1352-1358.
PMID: 37415296
The risk of severe adverse events related to thiopurine therapy can be reduced by personalizing dosing based on TPMT and NUDT15 genetic polymorphisms. However, the optimal genetic testing platform has...
10.
Duah E, Seligson N, Persaud A, Dam Q, Pabla N, Rocco J, et al.
Mol Carcinog
. 2023 May;
62(8):1201-1212.
PMID: 37132760
Head and neck squamous cell carcinoma (HNSCC) accounts for over 10,000 deaths in the United States annually. Approximately 80% of HNSCC are human papillomavirus (HPV)-negative which have an overall poorer...